March 30, 2020

BillionToOne, Inc. – $15 Million


Menlo Park, CA ; 03/11/2020

Amount Funded: $15 Million

Type: Series A+

Lead Investor: NeoTribe Ventures, Hummingbird Ventures

Participating Investor(s):  HOF Capital, Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul

Total Funding to Date: $32.5  Million

Company Description: BillionToOne, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company’s patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne’​s first product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother’s blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D.

What funding will be used for:  To support the commercial expansion of UNITY™ to all US states, research and development  of future diagnostics tests including liquid biopsy products.


“Since the launch of UNITY™ last summer, we faced a significant demand from the prenatal providers from community Ob/Gyns to top academic institutions throughout the US. We are planning to expand the capacity of our CLIA-licensed laboratory by more than 20x and our commercial team size up to 50 account executives to meet the demand. This additional funding will help us accelerate this expansion process.”

-Oguzhan Atay, Ph. D., co-founder/CEO, BillionToOne


Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.



StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →